| 2026-03-26 | Dr. James S. ShannonIndependent Director | 5,00k | 43,95k | Kauf | 8,79 | 10,00k | 100,00% |
| 2026-02-13 | Gilead Sciences, Inc.Unternehmen | 3,74M | 0,00 | Open Market Derivative Acquisition | 0,00 | 40,38M | 10,20% |
| 2026-01-01 | Dr. Rene RussoPresident, CEO & Director | 3,16k | 0,00 | Derivative Exercise and Retained Stock | - | 23,24k | 15,74% |
| 2026-01-01 | Mr. Kevin M. BrennanSVP of Finance & Accounting | 226,71 | 0,00 | Derivative Exercise and Retained Stock | - | 455,00 | 99,31% |
| 2026-01-01 | Mr. Kevin M. BrennanSVP of Finance & Accounting | -130,43 | 1,17k | Derivative Exercise and Sale | 9,00 | 455,00 | - |
| 2026-01-01 | Mr. Christopher FrankenfieldCFO & COO | 881,79 | 0,00 | Derivative Exercise and Retained Stock | - | 1,77k | 99,39% |
| 2026-01-01 | Mr. Christopher FrankenfieldCFO & COO | -502,14 | 4,52k | Derivative Exercise and Sale | 9,00 | 1,77k | - |
| 2026-01-01 | Dr. Katarina LuptakovaInsider | 1,19k | 0,00 | Derivative Exercise and Retained Stock | - | 2,38k | 100,00% |
| 2025-11-21 | Mr. Christopher FrankenfieldCFO & COO | -11,08k | 0,00 | Other Derivative Disposition | 21,00 | 11,08k | -50,00% |